Viemed HealthcareVMD

Key highlights

• Revenue outlook raised: The company increased the low end of its full year revenue forecast to a range of $314 million to $320 million, up from the prior floor of $312 million. This update signals confidence in demand despite a slight reduction in the expected profit range for the year.
• Sleep therapy patient growth: The number of patients using PAP therapy, which is a treatment for sleep apnea, grew 44% compared to last year to reach 37,825 people. This expansion in the sleep business is helping diversify the company away from its traditional focus on heavy-duty ventilators.
• Ventilator patient count record: Viemed reached a record 12,635 ventilator patients, which is a 4% increase from the same time last year. While this core business is still growing, it was outpaced by the much faster 46.7% growth in the number of patients buying recurring sleep supplies.
• Operating margins under pressure: Adjusted EBITDA, a measure of profit that excludes certain costs like interest and taxes, fell 4% to $13.7 million. This drop happened even as revenue rose, partly because the company no longer receives a $1 million one-time gain it had in the prior year from a ventilator return program.
• Efficient capital spending: Management lowered its expected spending on equipment to a range of 8.5% to 10% of revenue, down from the previous 9% to 10.5% range. This shift means the business is becoming less expensive to run as it grows more from services rather than just buying and renting out new machines.

Our take: A mixed quarter that shows the company is successfully changing its shape. While higher spending on growth initiatives weighed on earnings per share, the 44% jump in sleep therapy patients is building a more predictable, diversified business. This shift toward less expensive service revenue strengthens the long term case.